Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

Next Phase Research Alliance

Neither a doctor nor a teaching hospital

Research payments

$309,878

91 payments

Through program year 2024, Next Phase Research Alliance is reported as receiving $309,878 in research payments, across 91 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $21,770 4
2023 Research $6,003 1
2022 Research $112,298 21
2021 Research $96,851 36
2020 Research $53,161 23
2019 Research $19,795 6

Breakdown

Who paid Research payments · program years 2019–2024
  1. Pfizer Inc. $172,360 70 payments
  2. Merck Sharp & Dohme Corporation $55,230 2 payments
  3. VYNE Pharmaceuticals Inc. $50,997 13 payments
  4. Sanofi Pasteur Inc. $20,270 3 payments
  5. Novartis Pharmaceuticals Corporation $11,020 3 payments
Studies the money was for Research payments · program years 2019–2024
  1. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $121,497 20 payments
  2. A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants $53,610 1 payment
  3. Mti-105 $33,581 7 payments
  4. A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine in Healthy Infants $28,766 21 payments
  5. Mti-107 $17,416 6 payments
  6. A Phase 2 Randomized Openlabel Trial to Evaluate the Safety and Immunogenicity of A Multivalent Pneumococcal Conjugate Vaccine Given With Or Separately From 13Valent Pneumococcal Conjugate Vaccine in Healthy Infants $17,253 7 payments
  7. A Phase III, Partially Modified Double-blind, Randomized, Parallel-group, Active-controlled, Multi-center Study to Compare the Immunogenicity and Describe the Safety of MenACYW Conjugate Vaccine and MENVEO When Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in the United States $15,780 2 payments
  8. Observational Registry of Treatment Patterns in US Heart Failure Patients With Reduced Ejection Fraction $11,020 3 payments
  9. A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine in Healthy Infants $4,844 22 payments
  10. Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers $4,490 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record